M&A Deal Summary

Aurora Acquires H2 Biopharma

On November 23, 2017, Aurora acquired life science company H2 Biopharma for 25M CAD

Acquisition Highlights
  • This is Aurora’s 2nd transaction in the Life Science sector.
  • This is Aurora’s 3rd largest (disclosed) transaction.
  • This is Aurora’s 4th transaction in Canada.
  • This is Aurora’s 1st transaction in Quebec.

M&A Deal Summary
Date 2017-11-23
Target H2 Biopharma
Sector Life Science
Buyer(s) Aurora
Deal Type Add-on Acquisition
Deal Value 25M CAD

Target

H2 Biopharma

Lachute, Quebec, Canada
H2 Biopharma Inc. engages in the production and distribution of medical marijuana. H2 is currently completing a state-of-the-art, purpose-built 48,000 square foot cannabis production facility, less than an hour from Montreal (the "Lachute Facility"), and near the Pierre-Elliott Trudeau International Airport.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aurora

Edmonton, Alberta, Canada
Category Company
Founded 2013
Sector Life Science
Employees1,073
Revenue 270M CAD (2023)
DESCRIPTION

Aurora is a Canadian company and licensed producer of artisanal medical marijuana pursuant to the Marihuana for Medical Purposes Regulations. Aurora was founded in 2013 and is based in Edmonton, Alberta.

DEAL STATS #
Overall 5 of 13
Sector (Life Science) 2 of 5
Type (Add-on Acquisition) 5 of 12
State (Quebec) 1 of 1
Country (Canada) 4 of 10
Year (2017) 4 of 4
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-11-23 Larssen

Burlington, Ontario, Canada

Larssen Ltd. is a provider of high-tech, automated, environmentally controlled greenhouses. Larssen Ltd. is based in Burlington, Ontario.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-24 CanniMed Therapeutics

Saskatoon, Saskatchewan, Canada

CanniMed Therapeutics is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

Buy CA$1.1B
Mergr

Product

Company

Legal